Medicinal chemistry has a time problem. Planning a synthetic route, running the reactions, checking the results, then adjusting and repeating. Each loop can eat weeks of skilled hands at the bench. A new review in Medicinal Research Reviews looks at what happens when AI takes over the planning and robots take over the execution, and where that pairing actually holds up versus where it still falls short.
- AI is shifting from single-task predictors to connected platforms that link retrosynthesis, reaction optimization, and robotic execution into one loop.
- Closed-loop automation shortens cycle times and can cut the number of synthetic steps needed to reach a target.
- Sustainability becomes something you measure, with route choices judged on metrics like E-factor and process mass intensity.
- The authors stay grounded about the limits: data quality, reproducibility, and the real cost of deploying these systems.
- They call for shared benchmarks, such as step count and time to in vitro results, so progress can be compared honestly instead of anecdotally.
AI can plan a smarter route in seconds. The real speed shows up when the lab can build and analyze it end to end without manual handoffs, which is exactly the automation layer Chemspeed exists to deliver.
Authors and institutions: Amit Gangwal, School of Pharmacy and Technology Management, SVKM NMIMS Global University, Dhule, Maharashtra, India
Antonio Lavecchia (corresponding author), "Drug Discovery" Laboratory, Department of Pharmacy, University of Naples Federico II, Naples, Italy
Published in
Medicinal Research Reviews (Wiley)
https://doi.org/10.1002/med.70074
This summary is based on publicly available information and is shared for educational and informational purposes. All rights to the original publication remain with its authors and the publisher. No part of the original article is reproduced here, and full attribution with a link to the source is provided. Product and company names are the property of their respective owners.
